[
  {
    "criterion": "Accurately outlines the complete pneumococcal vaccination sequence for immunocompromised adults, including both initial vaccine selection and booster timing.",
    "points": 10,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Correctly identifies the current CDC-recommended pneumococcal vaccine options for immunocompromised adults: PCV15 followed by PPSV23, PCV20 alone, or PCV21 alone.",
    "points": 8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Specifies the correct timing between PCV15 and PPSV23 in immunocompromised adults (minimum interval of 8 weeks) versus the general adult population (1-year interval).",
    "points": 7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Correctly addresses the need for additional PPSV23 boosters for immunocompromised adults five years after the initial PPSV23 dose when applicable to their vaccination history.",
    "points": 7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Provides clear guidance on completing the pneumococcal vaccination series for immunocompromised adults with incomplete or partial vaccination histories.",
    "points": 6,
    "tags": [
      "level:example",
      "axis:completeness"
    ]
  },
  {
    "criterion": "Discusses considerations for timing pneumococcal vaccination in relation to immunosuppressive therapies or treatments.",
    "points": 5,
    "tags": [
      "level:example",
      "axis:context_awareness"
    ]
  },
  {
    "criterion": "Includes appropriate clinical terminology such as \"PCV\" (pneumococcal conjugate vaccine), \"PPSV23\" (pneumococcal polysaccharide vaccine), and serotype coverage when discussing vaccine options.",
    "points": 4,
    "tags": [
      "level:example",
      "axis:communication_quality"
    ]
  },
  {
    "criterion": "References the updated CDC guidance lowering the age for routine pneumococcal vaccination from 65 to 50 years (as of 2025).",
    "points": 3,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Fails to mention the need for additional PPSV23 boosters (beyond the initial PCV15â†’PPSV23 sequence) for immunocompromised adults.",
    "points": -9,
    "tags": [
      "level:example",
      "axis:completeness"
    ]
  },
  {
    "criterion": "Incorrectly states that PCV15, PCV20, and PCV21 all require PPSV23 follow-up in immunocompromised adults. (Justification: PCV20 and PCV21 are standalone vaccines that do not require PPSV23 follow-up, while PCV15 does require it.)",
    "points": -8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Provides outdated pneumococcal vaccination guidance (prior to 2024-2025 updates) without noting that the information may not reflect current recommendations.",
    "points": -7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Fails to differentiate between vaccination schedules for immunocompetent versus immunocompromised adults.",
    "points": -6,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Provides vague booster timing recommendations without specific intervals (e.g., \"get a booster later\" instead of \"5 years after initial PPSV23 dose\").",
    "points": -5,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Includes unnecessary technical details about vaccine composition, manufacturing processes, or historical development that distract from practical clinical guidance.",
    "points": -4,
    "tags": [
      "level:example",
      "axis:communication_quality"
    ]
  }
]